Shares of Mazor Robotics Ltd – (NASDAQ:MZOR) have been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the company. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $26.50.

Several equities research analysts recently commented on MZOR shares. Standpoint Research started coverage on shares of Mazor Robotics Ltd – in a research report on Friday, July 8th. They issued a “buy” rating and a $30.00 price objective on the stock. Barclays PLC boosted their price objective on shares of Mazor Robotics Ltd – from $16.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, July 14th. Zacks Investment Research lowered shares of Mazor Robotics Ltd – from a “buy” rating to a “hold” rating in a research report on Wednesday, September 14th. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics Ltd – in a research report on Thursday, July 7th. Finally, Sterne Agee CRT lowered shares of Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 31st.

Mazor Robotics Ltd – (NASDAQ:MZOR) traded up 0.946% on Wednesday, hitting $24.005. 67,027 shares of the stock traded hands. The stock’s market cap is $520.26 million. Mazor Robotics Ltd – has a 12-month low of $8.31 and a 12-month high of $24.79. The firm’s 50-day moving average price is $22.83 and its 200-day moving average price is $16.72.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mazor-robotics-ltd-nasdaqmzor-receives-consensus-recommendation-of-buy-from-analysts.html

Mazor Robotics Ltd – (NASDAQ:MZOR) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The business earned $8.30 million during the quarter, compared to analysts’ expectations of $8.51 million. During the same quarter in the prior year, the firm earned ($0.05) earnings per share. Mazor Robotics Ltd -‘s quarterly revenue was up 6.4% on a year-over-year basis. On average, equities research analysts anticipate that Mazor Robotics Ltd – will post ($0.71) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MZOR. EAM Investors LLC purchased a new position in Mazor Robotics Ltd – during the second quarter worth about $2,348,000. Iguana Healthcare Management LLC raised its position in Mazor Robotics Ltd – by 384.6% in the first quarter. Iguana Healthcare Management LLC now owns 121,151 shares of the company’s stock worth $1,507,000 after buying an additional 96,151 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in Mazor Robotics Ltd – during the second quarter worth about $1,079,000. Menta Capital LLC raised its position in Mazor Robotics Ltd – by 81.9% in the first quarter. Menta Capital LLC now owns 37,482 shares of the company’s stock worth $466,000 after buying an additional 16,879 shares during the period. Finally, Cookson Peirce & Co. Inc. purchased a new position in Mazor Robotics Ltd – during the second quarter worth about $192,000.

About Mazor Robotics Ltd –

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

5 Day Chart for NASDAQ:MZOR

Receive News & Ratings for Mazor Robotics Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.